Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
They are commonly prescribed for: Type 2 diabetes Chronic weight management Patients with obesity-related health risks Because they slow stomach emptying and reduce appetite, many people experience significant weight reduction while taking them
K.MoederW.YoshiokaK.BerkowitzG
Oral GLP-1 Race Heats Up Novo Nordisk and CORXEL Pharmaceuticals both made major movesNovo with FDA approval of oral Wegovy and Corxel with a $287M Series D to advance its oral GLP-1 candidatesignaling strong demand for non-injectable, scalable obesity therapies
Financial and insurance assistance If you need financial support to pay for NovoLog or help to understand your insurance coverage, help is available
